Vaughan Nelson Investment Management L.P. trimmed its stake in shares of Danaher Co. (NYSE:DHR – Free Report) by 30.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 630,275 shares of the conglomerate’s stock after selling 279,432 shares during the period. Danaher comprises 1.5% of Vaughan Nelson Investment Management L.P.’s holdings, making the stock its 18th largest position. Vaughan Nelson Investment Management L.P.’s holdings in Danaher were worth $157,474,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Tsfg LLC grew its holdings in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares during the period. Cape Investment Advisory Inc. acquired a new stake in Danaher in the fourth quarter valued at approximately $25,000. Redmont Wealth Advisors LLC acquired a new stake in Danaher in the first quarter valued at approximately $30,000. Wetzel Investment Advisors Inc. acquired a new stake in Danaher in the fourth quarter valued at approximately $29,000. Finally, Rakuten Securities Inc. acquired a new stake in Danaher in the fourth quarter valued at approximately $36,000. 79.05% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Linda Filler sold 3,928 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.50, for a total value of $1,097,876.00. Following the completion of the sale, the director now directly owns 41,149 shares of the company’s stock, valued at $11,501,145.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The disclosure for this sale can be found here. Insiders sold 38,707 shares of company stock worth $10,786,944 over the last 90 days. 11.10% of the stock is owned by insiders.
Analyst Ratings Changes
View Our Latest Stock Report on DHR
Danaher Trading Down 0.0 %
Shares of NYSE DHR traded down $0.01 during trading on Friday, reaching $269.32. The stock had a trading volume of 1,746,456 shares, compared to its average volume of 2,862,712. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The business’s 50-day moving average price is $257.69 and its 200-day moving average price is $253.51. The company has a market cap of $199.48 billion, a P/E ratio of 45.65, a PEG ratio of 4.62 and a beta of 0.83.
Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the firm posted $2.05 earnings per share. The company’s revenue was down 2.9% on a year-over-year basis. On average, equities research analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- Bank Stocks – Best Bank Stocks to Invest In
- This Small Cap Wealth Management Stock Could Provide Big Returns
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Conference Calls and Individual Investors
- MarketBeat Week in Review – 8/12 – 8/16
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.